Form 4: Gyre Therapeutics President Sells Shares Under 10b5-1 Plan

Songjiang Ma, President of Gyre Therapeutics, sold shares of common stock on March 11 and 12, 2025, under a pre-arranged 10b5-1 trading plan.

Summary

• Songjiang Ma, the President of Gyre Therapeutics, sold 2,000 shares of common stock on March 11, 2025, at a weighted average price of $11.40.
• The shares were sold in multiple transactions with prices ranging from $10.92 to $11.845.
• On March 12, 2025, Ma sold another 2,000 shares at a weighted average price of $11.74, with prices ranging from $11.40 to $12.135.
• These transactions were executed under a Rule 10b5-1 trading plan adopted on September 13, 2024.
• Following these transactions, Ma directly owns no shares, but his spouse indirectly owns 2,835,260 shares.

Sentiment

Score: 5

Explanation: The document is a routine filing related to stock sales under a pre-arranged plan, so it's neutral in sentiment.

Industry Context

Sales by company presidents are common and often pre-planned to avoid insider trading accusations. The use of a 10b5-1 plan suggests the sales were arranged in advance.

Stakeholder Impact

• The stock sales could have a minor impact on shareholders, potentially creating slight downward pressure on the stock price in the short term.

Key Dates